Page last updated: 2024-08-26

5,6-dihydro-5-azacytidine and Mesothelioma

5,6-dihydro-5-azacytidine has been researched along with Mesothelioma in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (75.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Green, MR; Kern, JA; Kindler, HL; Kratzke, MG; Kratzke, RA; Vogelzang, NJ; Vokes, EE; Wang, X; Wong, L	1
Antman, KH; Cirrincione, C; Citron, ML; Corson, JM; Green, MR; Harmon, DC; Herndon, JE; Suzuki, Y; Yogelzang, NJ	1
Aisner, J; Carey, R; Corson, JM; Green, MR; Harmon, DC; Herndon, JE; Samuels, BL; Suzuki, Y; Vogelzang, NJ	1
Dhingra, HM; Hong, WK; Murphy, WK; Raber, MN; Winn, RJ	1

Trials

3 trial(s) available for 5,6-dihydro-5-azacytidine and Mesothelioma

Article	Year
Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer, 1997, Jun-01, Volume: 79, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Arrhythmias, Cardiac; Azacitidine; Chest Pain; Female; Humans; Male; Mesothelioma; Middle Aged; Pleural Neoplasms	1997
Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Cancer, 1998, Apr-15, Volume: 82, Issue:8 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chest Pain; Cisplatin; Female; Humans; Leukopenia; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Prognosis; Survival Analysis	1998
Phase II trial of 5,6-dihydro-5-azacytidine in pleural malignant mesothelioma. Investigational new drugs, 1991, Volume: 9, Issue:1 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Drug Evaluation; Female; Humans; Male; Mesothelioma; Middle Aged; Pleural Neoplasms	1991

Other Studies

1 other study(ies) available for 5,6-dihydro-5-azacytidine and Mesothelioma

Article	Year
Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cyclin-Dependent Kinase Inhibitor p16; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mesothelioma; Middle Aged; Polymerase Chain Reaction; Prognosis; Survival Rate	2008

Article

Year

Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:4

Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cyclin-Dependent Kinase Inhibitor p16; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mesothelioma; Middle Aged; Polymerase Chain Reaction; Prognosis; Survival Rate

2008